First Time Loading...

Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319

Watchlist Manager
Chengdu Olymvax Biopharmaceuticals Inc Logo
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Watchlist
Price: 8.7 CNY 2.47% Market Closed
Updated: May 15, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Chengdu Olymvax Biopharmaceuticals Inc

Wall Street analysts forecast Chengdu Olymvax Biopharmaceuticals Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chengdu Olymvax Biopharmaceuticals Inc is 24.04 CNY .

Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
24.04 CNY
176% Upside
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
24.04 CNY
176% Upside
Highest
Price Target
Not Available
Chengdu Olymvax Biopharmaceuticals Inc Competitors:
Price Targets
XNCR
Xencor Inc
83% Upside
IGMS
IGM Biosciences Inc
135% Upside
C
688276
Changchun BCHT Biotechnology Co
60% Upside
DNLI
Denali Therapeutics Inc
113% Upside
XNCR
Xencor Inc
83% Upside
IGMS
IGM Biosciences Inc
135% Upside
C
688276
Changchun BCHT Biotechnology Co
60% Upside
DNLI
Denali Therapeutics Inc
113% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
85% Upside
VITR
Vitrolife AB
28% Upside
G
144510
GC Cell Corp
105% Upside
Y
YS
YS Biopharma Co Ltd
331% Upside

Revenue
Forecast

Revenue Estimate
Chengdu Olymvax Biopharmaceuticals Inc

For the last 3 years the compound annual growth rate for Chengdu Olymvax Biopharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 4 years is 18%.

45%
Past Growth
18%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Chengdu Olymvax Biopharmaceuticals Inc

The compound annual growth rate of Chengdu Olymvax Biopharmaceuticals Inc's operating income for the next 4 years is 36%.

N/A
Past Growth
36%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Chengdu Olymvax Biopharmaceuticals Inc

The compound annual growth rate of Chengdu Olymvax Biopharmaceuticals Inc's net income for the next 3 years is 96%.

N/A
Past Growth
96%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Chengdu Olymvax Biopharmaceuticals Inc's stock price target?
Price Target
24.04 CNY

According to Wall Street analysts, the average 1-year price target for Chengdu Olymvax Biopharmaceuticals Inc is 24.04 CNY .

What is Chengdu Olymvax Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 3 years the compound annual growth rate for Chengdu Olymvax Biopharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 4 years is 18%.

What is Chengdu Olymvax Biopharmaceuticals Inc's Operating Income forecast?
Projected CAGR
36%

The compound annual growth rate of Chengdu Olymvax Biopharmaceuticals Inc's operating income for the next 4 years is 36%.

What is Chengdu Olymvax Biopharmaceuticals Inc's Net Income forecast?
Projected CAGR
96%

The compound annual growth rate of Chengdu Olymvax Biopharmaceuticals Inc's net income for the next 3 years is 96%.

ALPHA SPREAD
Join more than 137,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.